Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival

New England Journal of Medicine

Volumn 334, Issue 11, 1996, Pages 701-706

  Kitahata, Mari M ^a   Koepsell, Thomas D ^a   Deyo, Richard A ^a   Maxwell, Clare L ^a   Dodge, Wayne T ^c   Wagner, Edward H ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL PRACTICE; HEALTH CARE DELIVERY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PHYSICIAN; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RESIDENCY EDUCATION; SURVIVAL RATE; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; CLINICAL COMPETENCE; COHORT STUDIES; FAMILY PRACTICE; HUMANS; INTERNAL MEDICINE; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS;

EID: 0029987128     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199603143341106     Document Type: Article

References (40)

1. Bennett CL, Garfinkle JB, Greenfield S, et al. The relation between hospital experience and in-hospital mortality for patients with AIDS-related PCP. JAMA 1989;261:2975-9.
2. Bennett CL, Adams J, Gertler P, et al. Relation between hospital experience and in-hospital mortality for patients with AIDS-related Pneumocystis carinii pneumonia: experience from 3,126 cases in New York City in 1987. J Acquir Immune Defic Syndr 1992;5:856-64
3. Turner BJ, Ball JK. Variations in inpatient mortality for AIDS in a national sample of hospitals. J Acquir Immune Defic Syndr 1992;5:978-87.
4. Stone VE, Seage GR III, Hertz T, Epstein AM The relation between hospital experience and mortality for patients with AIDS JAMA 1992;268: 2655-61.
5. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987;36:Suppl 1S:3S9S.
6. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17).1-19.
7. Ramsey PG, Wenrich MD, Carline JD, Curtis JR, Paauw DS. Primary care of patients with or at-risk for HIV infection: final report to the Agency for Health Care Policy and Research. Rockville, Md.. Department of Health and Human Services, 1994
8. Curtis JR, Paauw DS, Wenrich MD, Carline JD, Ramsey PG. Physicians' ability to provide initial primary care to an HIV-infected patient. Arch Intern Med 1995;155:1613-8
9. Graham NMH, Zeger SL, Kuo V, et al. Zidovudine use in AIDS-free HIV-1-seropositive homosexual men in the Multicenter AIDS Cohort Study (MACS), 1987-1989. J Acquir Immune Defic Syndr 1991;4 267-76.
10. Lang W, Osmond D, Samuel M, Moss A, Schrager L, Winkelstein W Jr. Population-based estimates of Zidovudine and aerosol pentamidine use in San Francisco: 1987-1989. J Acquir Immune Defic Syndr 1991,4 713-6.
11. Graham NM, Jacobson LP, Kuo V, Chmiel JS, Morgenstern H, Zucconi SL. Access to therapy in the Multicenter AIDS Cohort Study, 1989-1992. J Clin Epidemiol 1994;47.1003-12.
12. Holmberg SD, Conley LJ, Buchbinder SP, et al. Use of therapeutic and prophylactic drugs for AIDS by homosexual and bisexual men in three US cities AIDS 1993;7.699-704.
13. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322:941-9.
14. Munoz A, Schrager LK, Bacellar H, et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study 1985-1991. Am J Epidemiol 1993;137.423-38
15. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A Changes in AIDS survival time in two San Francisco cohorts of homosexual men. 1983 to 1993. JAMA 1994;271:1083-7.
16. Turner BJ, Markson LE, McKee LJ, Houchens R, Fanning T. The AIDS-defining diagnosis and subsequent complications: a survival-based severity index. J Acquir Immune Defic Syndr 1991;4:1059-71. [Erratum. J Acquir Immune Defic Syndr 1992;5:214 ]
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
19. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
20. Brown BW Jr, Hollander M. Statistics: a biomedical introduction. New York: John Wiley, 1977.
21. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42.121-30.
22. Yarchoan R, Venzon DJ, Pluda JM, et al. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy Ann Intern Med 1991;115:184-9.
23. Luft HS, Hunt SS, Maerki SC. The volume-outcome relationship: practice-makes-perfect or selective-referral patterns? Health Serv Res 1987;22:157-82.
24. Maerki SC, Luft HS, Hunt SS. Selecting categories of patients for regionalization: implications of the relationship between volume and outcome Med Care 1986;24:148-58.
25. Luft HS, Bunker JP, Enthoven AC. Should operations be regionalized? The empirical relation between surgical volume and mortality. N Engl J Med 1979;301:1364-9.
26. Markson LE, Cosler LE, Turner BJ. Implications of generalists' slow adoption of zidovudine in clinical practice. Arch Intern Med 1994;154.1497-504.
27. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med 1993,329:922-6.
28. Graham NM, Zeger SL, Park LP. et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS: the Multicenter AJDS Cohort Study. Lancet 1991;338:265-9.
29. Graham NMH, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992; 326:1037-42.
30. Chaisson RE, Keruly J, Richman DD, Moore RD Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine: the Zidovudine Epidemiology Group. Arch Intern Med 1992;152:2009-13.
31. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994;272:437-42.
32. Lundgren JD, Phillips AN, Pedersen C, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine AIDS in Europe Study Group. JAMA 1994;271:1088-92.
33. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial in immediate and deferred zidovudine in symptom-free HIV infection Lancet 1994;343:871-81.
34. Cotton DJ. Improving survival in acquired immunodeficiency syndrome: is experience everything? JAMA 1989;261:3016-7.
35. Shapiro MF, Greenfleld S. Experience and outcomes in AIDS JAMA 1992; 268:2698-9.
36. Northfelt DW, Hayward RA, Shapiro MF. The acquired immunodeficiency syndrome is a primary care disease. Ann Intern Med 1988;109:773-5.
37. Smith MD. Primary care and HIV disease. J Gen Intern Med 1991;6:Suppl 1 :S56-S62.
38. Makadon HJ, Delbanco SF, Delbanco TL. Caring for people with AIDS and HIV infection in hospital-based primary care practice. J Gen Intern Med 1990;5:446-50.
39. Volberding P The clinical spectrum of the acquired immunodeficiency syndrome: implications for comprehensive patient care. Ann Intern Med 1985; 103 729-33.
40. Vella S, Chiesi A, Volpi A, et al. Differential survival of patients with AIDS according to the 1987 and 1993 CDC case definitions. JAMA 1994; 271:1197-9.